Revocation of Certification of a Laboratory Which No Longer Meets Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 26106-26107 [E6-6657]

Download as PDF 26106 Federal Register / Vol. 71, No. 85 / Wednesday, May 3, 2006 / Notices Name of Committee: Oncological Sciences Integrated Review Group, Chemo/Dietary Prevention Study Section. Date: June 14–16, 2006 Time: 5 p.m to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Washington Embassy Row, 2015 Massachusetts Ave., NW., Washington, DC 20036. Contact Person: Sally A. Mulhern, PhD., Scientific Review Administrator, Center For Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6198, MSC 7804, Bethesda, MD 20892, (301) 435– 5877, mulherns@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos.; 93.306, Comparative Medicine; 93.333, Clinical Research; 93.306, 93.333, 93.337, 93.393–93.396, 93.837– 93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: April 25, 2006. David Clary, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–4147 Filed 5–2–06; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings jlentini on PROD1PC65 with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel Fellowship. Date: May 3, 2006. Time: 2 p.m. to 3 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Michael Micklin, PhD, Chief, RPHB IRG, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3136, MSC 7759, Bethesda, MD 20892, (301) 435–1258, micklinm@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing VerDate Aug<31>2005 19:53 May 02, 2006 Jkt 208001 limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel Prion Disease Regulation and Diagnostics. Date: May 4, 2006. Time: 2 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Richard G. Kostriken, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3192, MSC 7808, Bethesda, MD 20892, 301–402– 4454, kostrikr@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel, Bioengineering Research Partnership. Date: May 19, 2006. Time: 2 p.m. to 3 p.m. Agenda: To review and evaluate grant applications and/or proposals. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Pushpa Tandon, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5104, MSC 7854, Bethesda, MD 20892, 301–435– 2397, tandonp@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel, Member Conflict: BMIT and MEDI Study Sections. Date: May 21, 2006. Time: 7 p.m. to 10 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Silver Spring, 8727 Colesville Road, Silver Spring, MD 20910. Contact Person: Weihua Luo, MD, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5114, MSC 7854, Bethesda, MD 20892, (301) 435– 1170, luow@csr.nih.gov. Name of Committee: Cardiovascular Sciences Integrated Review Group, Cardiovascular Differentiation and Development Study Section. Date: June 12–13, 2006. Time: 8:30 a.m. to 3 p.m. Agenda: To review and evaluate grant applications. Place: Gaithersburg Marriott Washingtonian Center, 9751 Washingtonian Boulevard, Gaithersburg, MD 20878. Contact Person: Maqsood A. Wani, PhD, DVM, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2114, MSC 7814, Bethesda, MD 20892, (301) 435–2270, wanimaqs@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel, Social Science and Population Studies RO3s, R15s, R21s and Fellowships. Date: June 16, 2006. PO 00000 Frm 00089 Fmt 4703 Sfmt 4703 Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015. Contact Person: Valerie Durrant, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3148, MSC 7770, Bethesda, MD 20892, (301) 435– 3554, durrantv@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos.; 93.306, Comparative Medicine; 93.333, Clinical Research; 93.306, 93.333, 93.337, 93.393–93.396, 93.837– 93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: April 25, 2006. David Clary, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–4148 Filed 5–2–06; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Revocation of Certification of a Laboratory Which No Longer Meets Minimum Standards To Engage in Urine Drug Testing for Federal Agencies Substance Abuse and Mental Health Services Administration, HHS. ACTION: Notice. AGENCY: SUMMARY: The Department of Health and Human Services routinely publishes a list of laboratories in the Federal Register that are currently certified to meet standards of Subpart C of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908), on September 30, 1997 (62 FR 51118), and on April 13, 2004 (69 FR 19644). This notice informs the public that the following laboratory’s certification was revoked effective February 8, 2006: Sciteck Clinical Laboratories, Inc., 317 Rutledge Road, Fletcher, North Carolina 28732. The letter describing the reasons for revoking Sciteck’s certification is available on the Internet at https:// workplace.samhsa.gov. FOR FURTHER INFORMATION CONTACT: Dr. Donna Bush, Division of Workplace Programs, SAMHSA/CSAP, Room \\ALPHA3\E\FR\FM\03MYN1.SGM 03MYN1 Federal Register / Vol. 71, No. 85 / Wednesday, May 3, 2006 / Notices Alternatives Process in Hydropower Licensing,’’ OMB control #1094–0001), and explanatory information and related forms, contact Sue Ellen Sloca, U.S. Department of the Interior, National Business Center, MS 1413 MIB, 1849 C St., NW., Washington, DC 20240, phone 202–208–6045, fax 202–219–2374, or by electronic mail to sue_ellen_sloca@nbc.gov. 2–1035, 1 Choke Cherry Road, Rockville, Maryland 20857; 240–276– 2600 (voice), 240–276–2610 (fax). Anna Marsh, Director, Office of Program Services, SAMHSA. [FR Doc. E6–6657 Filed 5–2–06; 8:45 am] BILLING CODE 4162–20–P SUPPLEMENTARY INFORMATION: DEPARTMENT OF THE INTERIOR I. Abstract Office of the Secretary Notice of Proposed Information Collection Office of the Secretary, Office of Hearings and Appeals. ACTION: Notice and request for comments. jlentini on PROD1PC65 with NOTICES AGENCY: SUMMARY: The proposal for the collection of information listed below has been submitted to the Office of Management and Budget (OMB) for approval under the provisions of the Paperwork Reduction Act (44 U.S.C. chapter 35). Copies of the proposed information collection request may be obtained by contacting the Clearance Officer at the phone number listed below. Comments and suggestions on the requirement should be made directly to the Office of Management and Budget. A copy of the comments and suggestions should also be sent to the Clearance Officer. DATES: OMB has up to 60 days to approve or disapprove the information collection, but may respond after 30 days. Therefore, public comments should be submitted to OMB by June 2, 2006, in order to be assured of consideration. ADDRESSES: Send your written comments to Office of Management and Budget, Office of Information and Regulatory Affairs, Attention, Department of the Interior Desk Officer, by fax to 202–395–6566, or by e-mail to oira_docket@omb.eop.gov. Send a copy of your written comments to Sue Ellen Sloca, U.S. Department of the Interior, National Business Center, MS 1413 MIB, 1849 C St., NW., Washington, DC 20240, phone 202–208–6045, fax 202–219– 2374, or electronically to sue_ellen_sloca@nbc.gov. Please mention that your comments concern ‘‘7 CFR Part 1; 43 CFR Part 45; 50 CFR Part 221; the Alternatives Process in Hydropower Licensing,’’ OMB control #1094–0001. FOR FURTHER INFORMATION CONTACT: To request a copy of the information collection request (‘‘7 CFR Part 1; 43 CFR Part 45; 50 CFR Part 221; the VerDate Aug<31>2005 22:12 May 02, 2006 Jkt 208001 The Office of Management and Budget (OMB) regulations at 5 CFR part 1320, which implement the Paperwork Reduction Act of 1995 (Pub. L. 104–13), require that interested members of the public and affected agencies have an opportunity to comment on information collection and recordkeeping activities (see 5 CFR 1320.8(d)). This notice identifies an information collection activity that the Office of Hearings and Appeals has submitted to OMB for extension or re-approval. On November 17, 2005, the Departments of Agriculture, Interior, and Commerce published regulations at 7 CFR part 1, 43 CFR part 45, and 50 CFR part 221, to implement section 241 of the Energy Policy Act of 2005 (EPAct), Public Law 109–58, which the President signed into law on August 8, 2005. Section 241 of the EPAct adds a new section 33 to the Federal Power Act (FPA) that allows the license applicant or any other party to the license proceeding to propose an alternative to a condition or prescription that one or more of the Departments develop for inclusion in a hydropower license issued by the Federal Energy Regulatory Commission (FERC) under the FPA. This provision requires that the Departments of Agriculture, Interior and Commerce collect the information covered by 1094–0001. The Secretary of the Department involved must accept the proposed alternative if the Secretary determines, based on substantial evidence provided by a party to the license proceeding or otherwise available to the Secretary, (a) that the alternative condition provides for the adequate protection and utilization of the reservation, or that the alternative prescription will be no less protective than the fishway initially proposed by the Secretary, and (b) that the alternative will either cost significantly less to implement or result in improved operation of the project works for electricity production. In order to make this determination, the regulations require that all of the following information be collected: (1) A description of the alternative, in an PO 00000 Frm 00090 Fmt 4703 Sfmt 4703 26107 equivalent level of detail to the bureau’s preliminary condition or prescription; (2) an explanation of how the alternative: (i) If a condition, will provide for the adequate protection and utilization of the reservation; or (ii) if a prescription, will be no less protective than the fishway prescribed by the bureau; (3) an explanation of how the alternative, as compared to the preliminary condition or prescription, will: (i) Cost significantly less to implement; or (ii) result in improved operation of the project works for electricity production; (4) an explanation of how the alternative or revised alternative will affect: (i) Energy supply, distribution, cost, and use; (ii) flood control; (iii) navigation; (iv) water supply; (v) air quality; and (vi) other aspects of environmental quality; and (5) specific citations to any scientific studies, literature, and other documented information relied on to support the proposal. This notice of proposed information collection is being published by the Office of Hearings and Appeals, Department of the Interior, on behalf of all three Departments, and the data provided below covers anticipated responses (alternative conditions/ prescriptions and associated information) for all three Departments. II. Data (1) Title: 7 CFR Part 1; 43 CFR Part 45; 50 CFR Part 221; the Alternatives Process in Hydropower Licensing. OMB Control Number: 1094–0001. Current Expiration Date: May 31, 2006. Type of Review: Information Collection Renewal. Affected Entities: Business or forprofit entities. Estimated annual number of respondents: 30. Frequency of response: Once per alternative proposed. (2) Annual reporting and recordkeeping burden: Total annual reporting per response: 150 hours. Total number of estimated responses: 250. Total annual reporting: 37,500 hours. (3) Description of the need and use of the information: The purpose of this information collection is to provide an opportunity for license parties to propose an alternative condition or prescription to that imposed by the Federal Government in the hydropower licensing process. III. Request for Comments The Departments invite comments on: (a) Whether the collection of information is necessary for the proper E:\FR\FM\03MYN1.SGM 03MYN1

Agencies

[Federal Register Volume 71, Number 85 (Wednesday, May 3, 2006)]
[Notices]
[Pages 26106-26107]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-6657]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Revocation of Certification of a Laboratory Which No Longer Meets 
Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Department of Health and Human Services routinely 
publishes a list of laboratories in the Federal Register that are 
currently certified to meet standards of Subpart C of the Mandatory 
Guidelines for Federal Workplace Drug Testing Programs (Mandatory 
Guidelines). The Mandatory Guidelines were first published in the 
Federal Register on April 11, 1988 (53 FR 11970), and subsequently 
revised in the Federal Register on June 9, 1994 (59 FR 29908), on 
September 30, 1997 (62 FR 51118), and on April 13, 2004 (69 FR 19644).
    This notice informs the public that the following laboratory's 
certification was revoked effective February 8, 2006: Sciteck Clinical 
Laboratories, Inc., 317 Rutledge Road, Fletcher, North Carolina 28732.
    The letter describing the reasons for revoking Sciteck's 
certification is available on the Internet at https://
workplace.samhsa.gov.

FOR FURTHER INFORMATION CONTACT: Dr. Donna Bush, Division of Workplace 
Programs, SAMHSA/CSAP, Room

[[Page 26107]]

2-1035, 1 Choke Cherry Road, Rockville, Maryland 20857; 240-276-2600 
(voice), 240-276-2610 (fax).

Anna Marsh,
Director, Office of Program Services, SAMHSA.
[FR Doc. E6-6657 Filed 5-2-06; 8:45 am]
BILLING CODE 4162-20-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.